Skip to main content

Monash University’s vital role in advancing global prostate cancer research

A landmark clinical trial, ENZAMET has highlighted the contribution of universities in advancing medical research across the world.

The ENZAMET trial is led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group, chaired by Professor Ian Davis, Head of the Eastern Health Clinical School at Monash University, who is also global co-chair of ENZAMET. ENZAMET initially opened as an academic study in Australia and New Zealand, rapidly involving sites in Canada, Ireland, the United Kingdom and the United States. It accrued 1,125 participants between 2014 and 2017. 

At its first interim analysis in 2019, ENZAMET demonstrated a 33 per cent reduction in the hazard of death among men with prostate cancer using enzalutamide, a novel hormone therapy. 

‘The findings from ENZAMET have been included in treatment guidelines around the world and could make a big difference to thousands of men who are diagnosed with metastatic prostate cancer,’ said Professor Davis. ‘This trial has put investigator-initiated cancer research in the spotlight, on a global scale.’

‘It demonstrates the important role universities play in advancing medical research across the world and the direct benefits a supported medical research sector can deliver to people living with cancer and many other diseases too,’ said Professor Davis.

ENZAMET was the recipient of a prestigious trifecta of awards from the Australian Clinical Trials Alliance (ACTA) award in 2020. These include the ACTA Trial of the Year Award, the ACTA STInG Excellence in Trial Statistics Award, and the ACTA Consumer Involvement Award.